The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK- transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.Linvention concerne des composés représentés par la formule (I) : Qui inhibent, régulent et/ou modulent P13K et/ou mTOR et qui conviennent pour le traitement de maladies hyperprolifératives telles que le cancer, chez les mammifères. Cette invention concerne également des méthodes de fabrication de tels composés et de leur utilisation pour le traitement de maladies hyperprolifératives, telles que le cancer, chez les mammifères, en particulier chez les humains, et des compositions pharmaceutiques contenant ces composés. Les cancers, par exemple, dans lesquels lactivité contre P13fC- alph mTOR ou les deux, contribuent à leur pathologie et/ou symptomatologie. Soit : cancer du sein, lymphome à cellules du manteau, carcinome des cellules rénales, leucémie myélogène aiguë, leucémie myélogène chronique, lymphome anaplasique à grandes ce
